Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Phase I/II Clinical Trial of SYS6043 Monotherapy or SYS6043 Combined With PD-1/VEGF Bispecific Antibody ± Chemotherapy in the Treatment of Advanced Solid Tumors.

16. november 2026 oppdatert av: CSPC Megalith Biopharmaceutical Co.,Ltd.

An Open-label, Multicenter Phase I/II Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SYS6043 Monotherapy or SYS6043 Combined With PD-1/VEGF Bispecific Antibody ± Chemotherapy in Patients With Advanced Solid Tumors.

This is a multicenter phase 1/2 clinical study to evaluate the efficacy and safety of SYS6043 monotherapy or SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy in patients with advanced solid tumors.

Studieoversikt

Detaljert beskrivelse

The Phase I study is a a dose-escalation study, comprises dose escalation for the doublet regimen and dose escalation for the triplet regimen. The Phase II study isa cohort expansion study.

Phase I: the dose escalation use a 3+3 design. The doublet regimen consists of SYS6043 + PD-1/VEGF bispecific antibody. The triplet regimen consists of SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy.

The Phase II study will be conducted as an expansion in 6 cohorts, with indications including triple-negative breast cancer, small cell lung cancer, non-small cell lung cancer, etc.

Studietype

Intervensjonell

Registrering (Antatt)

368

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Be able to understand and voluntarily sign and datethe written ICF prior to any trial-related procedure;
  2. Age 18-75 (inclusive) years;
  3. Histologically or cytologically confirmed advanced/unresectable or metastatic solid tumors(specific cohort requirements apply, including TNBC, SCLC, and driver-gene negative NSCLC based on UICC/AJCC 8th edition staging);
  4. Dose escalation phase: evaluable lesions per RECIST v1.1. Dose expansion phase: at least one extracranial measurable lesion per RECIST v1.1. Lesions previously treated with radiotherapy or other local therapy may not be selected as target lesions unless there is clear evidence of progression.
  5. Qualified archived or fresh tumor tissue samples must be provided; participants who cannot provide tumor samples or whose samples are insufficient may be enrolled based on individual circumstances.
  6. Eastern Cooperative Oncology Group (ECOG) performance status score: 0-1;
  7. Adequate organ and bone marrow function within 7 days prior to the first dose, as defined below.
  8. Life expectancy ≥ 3 months;
  9. Female participants of childbearing age must have a negative serum pregnancy test within 7 days before dosing. Male and female participants of reproductive potential must agree to use adequate contraception during the study and for at least 7 months after the last dose of the investigational product; during this period, female participants must not be breastfeeding, male participants must not freeze or donate sperm, and female participants must not donate eggs or undergo egg retrieval for personal use.

Exclusion Criteria:

  1. Combined SCLC (i.e., mixed large cell carcinoma, squamous cell carcinoma, spindle/pleomorphic and/or large cell components) and transformed SCLC.
  2. Prior history of CTCAE grade ≥3 immune-related adverse events (irAEs) during treatment with anti-PD-(L)1 or other immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy, or other therapies targeting tumor immune mechanisms, except for endocrine disorders such as hyperglycemia or hypothyroidism that have recovered to grade ≤2.
  3. Prior treatment with B7-H3-targeted therapies (including antibodies, antibody-drug conjugates [ADCs], chimeric antigen receptor T-cell [CAR-T] therapies, and other agents).
  4. Prior treatment with a topoisomerase I inhibitor antibody-drug conjugate or a topoisomerase I inhibitor.
  5. Toxicities from prior antitumor therapy have not resolved to CTCAE grade ≤1 or to the levels specified in the inclusion/exclusion criteria (except alopecia and hyperpigmentation).
  6. History of underlying pulmonary disease, including but not limited to severe asthma, severe COPD, restrictive lung disease, and other clinically significant pulmonary impairment or requirement for supplemental oxygen.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: SYS6043+PD-1/VEGF bispecific antibody

SYS6043: IV PD-1/VEGF bispecific antibody: IV

Eksperimentell: SYS6043 combined with PD-1/VEGF bispecific antibody +chemotherapy.

SYS6043: IV PD-1/VEGF bispecific antibody: IV Chemotherapy: cisplatin or carboplatin, IV

Eksperimentell: SYS6043 monotherapy

SYS6043: IV

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Phase I: Incidences of AEs
Tidsramme: From the signing of the informed consent form until 90 days after the last dose.
From the signing of the informed consent form until 90 days after the last dose.
Phase I: DLT
Tidsramme: 21 days

Dose-limiting toxicity

21 days
Phase I: MTD/RP2D
Tidsramme: After phase I dose escalation stage. Approximately 4 months.

Maximum Tolerated Dose/ Recommended Phase II Dose

After phase I dose escalation stage. Approximately 4 months.
Phase II: ORR
Tidsramme: Up to 2 years

Objective response rate

Up to 2 years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Phase I: ORR
Tidsramme: Up to 2 years

Objective response rate

Up to 2 years
Phase I:DCR
Tidsramme: Up to 2 years

Disease control rate

Up to 2 years
Phase I:DOR
Tidsramme: Up to 2 years

Duration of response

Up to 2 years
Phase I: TTR
Tidsramme: Up to 2 years

Time to Response

Up to 2 years
Phase I: PFS
Tidsramme: Up to 2 years

Progression free survival

Up to 2 years
Phase I:OS
Tidsramme: Up to 3 years

Overall survival

Up to 3 years
Phase I:Plasma concentrations of SYS6043, total antibody, and free JS-1.
Tidsramme: Up to 2 years
Up to 2 years
Phase I:Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) for SYS6043.
Tidsramme: Up to 2 years
Up to 2 years
Phase I:Expression levels of proteins such as B7-H3 and PD-L1 in tumor tissue.
Tidsramme: Up to 2 years
Up to 2 years
Phase II:DCR
Tidsramme: Up to 2 years

Disease control rate

Up to 2 years
Phase II:DOR
Tidsramme: Up to 2 years

Duration of response

Up to 2 years
Phase II: TTR
Tidsramme: Up to 2 years

Time to Response

Up to 2 years
Phase II: PFS
Tidsramme: Up to 2 years

Progression free survival

Up to 2 years
Phase II:OS
Tidsramme: Up to 3 years
Up to 3 years
Title: Phase II: Incidences of AEs
Tidsramme: From the signing of the informed consent form until 90 days after the last dose.

Overall survival

From the signing of the informed consent form until 90 days after the last dose.
Phase II:Plasma concentrations of SYS6043, total antibody, and free JS-1.
Tidsramme: Up to 2 years
Up to 2 years
Phase II:Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) for SYS6043.
Tidsramme: Up to 2 years
Up to 2 years
Phase II:Expression levels of proteins such as B7-H3 and PD-L1 in tumor tissue.
Tidsramme: Up to 2 years
Up to 2 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

30. desember 2026

Primær fullføring (Antatt)

30. desember 2028

Studiet fullført (Antatt)

30. desember 2029

Datoer for studieregistrering

Først innsendt

13. november 2026

Først innsendt som oppfylte QC-kriteriene

16. november 2026

Først lagt ut (Faktiske)

20. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • SYS6043-005

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere